UroGen Pharma Ltd. — Director's Dealing 2020

Oct 5, 2020

SEC Form 4/A — Form 4/A

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2020-10-01

Reporting Person: Smith Jason Drew (General Counsel)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-01	Employee Stock Option (right to buy)	$19.66	A	60000	Acquired	2030-09-30	Ordinary Shares (60000)	Direct
2020-10-01	Restricted Stock Unit	$	A	25000	Acquired		Ordinary Shares (25000)	Direct

Footnotes

F1: The stock options and restricted stock units represented on the original Form 4 were not granted to the reporting person until October 1, 2020, following approval by the Issuer's Compensation Committee on that date.

F2: 1/3 of the shares underlying the stock option will vest on each of August 31, 2021, August 31, 2022 and August 31, 2023.

F3: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.

F4: 1/3 of the shares underlying the restricted stock units will vest on each of August 31, 2021, August 31, 2022 and August 31, 2023.